Clinical trials: Rivaroxaban
Ischemic Stroke, Patent Foramen Ovale
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.
- Trial name
- PACIFIC-PFO (NCT06983795)
- Testing
- PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management
- Where
- Singapore
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Venous Thromboembolism
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Rationale: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE) or deep venous thrombosis (DVT) potentially resulting in a fatal pulmonary embolism (PE).
- Trial name
- DARINA (NCT01431456)
- Testing
- Dabigatran, Rivaroxaban, Nadroparin
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Martini Hospital Groningen
Direct Oral Anticoagulants (DOACs), Oral Surgical Procedures
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited.
- Trial name
- DOACS_BX (NCT07520890)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Venous Thromboembolism, Urologic Cancer
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy).
- Trial name
- PREVENT-GU (NCT05920343)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Ottawa Hospital Research Institute
Pulmonary Embolism
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs). 2.
- Trial name
- NCT06362343
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Healthy Volunteers
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability and Pharmacokinetics/Pharmacodynamics of multiple doses of GCC-4401C in healthy male subjects.
- Trial name
- NCT01954238
- Testing
- GCC-4401C, Rivaroxaban
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Venous Thromboembolism
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
The main goal is to provide additional information to the risk-benefit assessment of the drug.
- Trial name
- XAMOS (NCT00831714)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard care treatment for VTE prophylaxis
- Where
- 42 sites in Australia, Austria and 40 more
- Volunteers
- 19,076 people
- Sponsor
- Bayer
Deep Vein Thrombosis
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
The treatment of isolated distal deep vein thrombosis remains one of the most debated issues in the field of venous thromboembolism and only very few studies have directly addressed the issue of treatment in objectively confirmed…
- Trial name
- RIDTS (NCT02722447)
- Testing
- rivaroxaban
- Where
- 7 sites in Italy
- Volunteers
- 1,100 people
- Sponsor
- Walter Ageno
Therapeutic Equivalency
Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
The drug investigated in this study is Rivaroxaban, a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or…
- Trial name
- NCT01436526
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bayer
Antiphospholipid Syndrome, Systemic Lupus Erythematosus
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.
- Conditions
- Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke
- Trial name
- RISAPS (NCT03684564)
- Testing
- Rivaroxaban, Warfarin
- Where
- 6 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- University College, London
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Deep Vein Thrombosis, Pulmonary Embolus
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05083455
- Testing
- Rivaroxaban, Enoxaparin
- Where
- United States
- Volunteers
- 89,215 people
- Sponsor
- Brigham and Women's Hospital
Anticoagulation
Patient and Physician Knowledge of Key Safety Messages
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
- Trial name
- NCT01907048
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 2,227 people
- Sponsor
- Bayer
Atrial Fibrillation
The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery
A small pilot study comparing different blood thinners (non-vitamin K oral anticoagulants [NOACs] and warfarin) will be conducted in people at risk for blood clots after open-heart surgery.
- Trial name
- NCT05006287
- Testing
- Non-vitamin K oral anticoagulants (NOACs), Warfarin
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- St. Paul's Hospital, Canada
Pulmonary Embolism
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total…
- Trial name
- MERCURY PE (NCT02584660)
- Testing
- Rivaroxaban, Standard-of-care
- Where
- 50 sites in United States
- Volunteers
- 114 people
- Sponsor
- Janssen Scientific Affairs, LLC
Patent Foramen Ovale, Migraine
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Migraine attack is an episodic disorder that affects approximately 12% of the population. Previous studies have shown that 41-48% of migraineur have a combination of patent foramen ovale (PFO).
- Trial name
- COMPETE (NCT05546320)
- Testing
- Aspirin 300mg, Metoprolol 25mg, Clopidogrel 75mg
- Where
- 39 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Deep Vein Thrombosis, Post Thrombotic Syndrome
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs.
- Trial name
- TILE (NCT04794569)
- Testing
- tinzaparin, Rivaroxaban
- Where
- 5 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Sunnybrook Health Sciences Centre
Stroke, Prevention
Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year.
- Trial name
- AREST-ESUS (NCT04273516)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- Iran
- Volunteers
- 42 people
- Sponsor
- Mazandaran University of Medical Sciences
Cerebrosinovenous Thrombosis
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard…
- Trial name
- NCT07523347
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- Muhammad Aamir Latif
Atrial Fibrillation, Cerebrothromboembolus
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States, and treatment by AF ablation is quickly becoming the favored definitive therapy.
- Conditions
- Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function
- Trial name
- NCT02120560
- Testing
- Atrial Fibrillation Ablation
- Where
- United States
- Sponsor
- University of California, San Francisco